cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Enanta Pharmaceuticals Inc
1 own
5 watching
Current Price
$54.59
$1.65
(3.12%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,134.98M
52-Week High
52-Week High
79.495
52-Week Low
52-Week Low
37.59
Average Volume
Average Volume
0.12M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
363.2224
iconMarket Capitalization1,134.98M
icon52-Week High79.495
icon52-Week Low37.59
iconAverage Volume0.12M
iconDividend Yield--
iconP/E Ratio363.2224
What does the Enanta Pharmaceuticals Inc do?
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on four disease targets: Hepatitis C virus (HCV), Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). Its lead product is paritaprevir, a protease inhibitor designed for use against HCV. The company also develops HCV protease inhibitor in phase III development with AbbVie, as well as a HCV program using a different class of molecules known as cyclophilin inhibitors. In addition, it has a program in non-alcoholic steatohepatitis; and discovers programs in other areas of viral infection and liver disease. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Read More
How much money does Enanta Pharmaceuticals Inc make?
News & Events about Enanta Pharmaceuticals Inc.
Ticker Report
8days ago
Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA Get Rating) have received an average rating of Moderate Buy from the nine ratings firms that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and ...
Business Wire
1month ago
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., Enantas President and Chief Executive Officer, will provide an update across its pipeline of virology programs...
Ticker Report
2 months ago
Enanta Pharmaceuticals (NASDAQ:ENTA Get Rating)s stock had its buy rating reaffirmed by equities research analysts at JMP Securities in a research report issued on Tuesday, Stock Target Advisor reports. They presently have a $96.00 price objective on the biotechnology ...
Business Wire
5 months ago
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data for EDP-235, its lead oral coronavirus protease inhibitor specifically designed for the...
Zolmax
6 months ago
Enanta Pharmaceuticals (NASDAQ:ENTA Get Rating) had its price objective hoisted by JMP Securities from $103.00 to $137.00 in a research report report published on Tuesday , The Fly reports. They currently have a market outperform rating on the biotechnology companys stock. Other equities research ...
Frequently Asked Questions
Frequently Asked Questions
What is Enanta Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Enanta Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Enanta Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Enanta Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Enanta Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Enanta Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Enanta Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Enanta Pharmaceuticals Inc?
plus_minus_icon
What percentage is Enanta Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Enanta Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$54.59
$1.65
(3.12%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00